Identification and characterization of potent CYP3A4 inhibitors in Schisandra fruit extract

被引:145
作者
Iwata, H
Tezuka, Y
Kadota, S
Hiratsuka, A
Watabe, T
机构
[1] Toyama Med & Pharmaceut Univ, Inst Nat Med, Div Nat Prod Chem, Toyama 9300194, Japan
[2] Mitsubishi Chem Safety Inst Ltd, Div Anal & Metab, Kashima Lab, Ibaraki, Japan
[3] Tokyo Univ Pharm & Life Sci, Dept Drug Metab & Mol Toxicol, Tokyo, Japan
[4] Nihon Pharmaceut Univ, Dept Mol Toxicol, Saitama, Japan
关键词
D O I
10.1124/dmd.104.000646
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Schisandra fruit, a Schisandraceae family herb, is used as a component in Kampo medicines (developed from Chinese medicines, but established in Japan). It can act as a sedative and antitussive, improve hepatic function, and give a general tonic effect. An extract of Schisandra fruit has been shown with a potent inhibitory effect on human liver microsomal erythromycin N-demethylation activity mediated by cytochrome P450 3A4 (CYP3A4). The present study was conducted to identify Schisandra fruit components having inhibitory effects on CYP3A4 by surveying the effect on human liver microsomal erythromycin N-demethylation activity. Known components of Schisandra fruit, gomisins B, C, G, and N and gamma-shizandrin, showed inhibitory effects on N-demethylation activity. Among these components, gomisin C displayed the most potent and competitive inhibitory effect, with a K-i value of 0.049 muM. Furthermore, the inhibitory effect of gomisin C was stronger than that of ketoconazole (K-i=0.070 muM), a known potent CYP3A4 inhibitor. Gomisin C, however, inhibited CYP1A2-, CYP2C9-, CYP2C19-, and CYP2D6-dependent activities only to a limited extent (IC50 values>10 muM). Moreover, gomisin C inactivated human liver microsomal erythromycin N-demethylation activity in a time- and concentration-dependent manner. The inactivation kinetic parameters k(inact) and K-I were 0.092 min(-1) and 0.399 muM, respectively. The human liver microsomal erythromycin N-demethylation activity inactivated by gomisin C did not recover on dialysis of the microsomes. Spectral scanning of CYP3A4 with gomisin C yielded an absorbance at 455 nm, suggesting that gomisin C inactivated the cytochrome P450 via the formation of a metabolite intermediate complex. This pattern is consistent with the metabolism of the methylenedioxy substituent in gomisin C. These results indicate that gomisin C is a mechanism-based inhibitor that not only competitively inhibits but irreversibly inactivates CYP3A4.
引用
收藏
页码:1351 / 1358
页数:8
相关论文
共 36 条
[1]  
[Anonymous], MECHANISM BASED ENZY
[2]   GRAPEFRUIT JUICE FELODIPINE INTERACTION - MECHANISM, PREDICTABILITY, AND EFFECT OF NARINGIN [J].
BAILEY, DG ;
ARNOLD, JMO ;
MUNOZ, C ;
SPENCE, JD .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1993, 53 (06) :637-642
[3]   EFFECT OF GRAPEFRUIT JUICE AND NARINGIN ON NISOLDIPINE PHARMACOKINETICS [J].
BAILEY, DG ;
ARNOLD, JMO ;
STRONG, HA ;
MUNOZ, C ;
SPENCE, JD .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1993, 54 (06) :589-594
[4]   Drug interaction between St. John's wort and cyclosporine [J].
Barone, GW ;
Gurley, BJ ;
Ketel, BL ;
Lightfoot, ML ;
Abul-Ezz, SR .
ANNALS OF PHARMACOTHERAPY, 2000, 34 (09) :1013-1016
[5]   HEPATIC-MICROSOMAL TOLBUTAMIDE HYDROXYLATION IN JAPANESE - INVITRO EVIDENCE FOR RAPID AND SLOW METABOLIZERS [J].
CHEN, LS ;
YASUMORI, T ;
YAMAZOE, Y ;
KATO, R .
PHARMACOGENETICS, 1993, 3 (02) :77-85
[6]   TROUGH CONCENTRATIONS OF CYCLOSPORINE IN BLOOD FOLLOWING ADMINISTRATION WITH GRAPEFRUIT JUICE [J].
DUCHARME, MP ;
PROVENZANO, R ;
DEHOORNESMITH, M ;
EDWARDS, DJ .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1993, 36 (05) :457-459
[7]   In vitro techniques for studying drug metabolism [J].
Guengerich, FP .
JOURNAL OF PHARMACOKINETICS AND BIOPHARMACEUTICS, 1996, 24 (05) :521-533
[8]   CHANGES IN THE PHARMACOKINETICS AND ELECTROCARDIOGRAPHIC PHARMACODYNAMICS OF TERFENADINE WITH CONCOMITANT ADMINISTRATION OF ERYTHROMYCIN [J].
HONIG, PK ;
WOOSLEY, RL ;
ZAMANI, K ;
CONNER, DP ;
CANTILENA, LR .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1992, 52 (03) :231-238
[9]   TERFENADINE-KETOCONAZOLE INTERACTION - PHARMACOKINETIC AND ELECTROCARDIOGRAPHIC CONSEQUENCES [J].
HONIG, PK ;
WORTHAM, DC ;
ZAMANI, K ;
CONNER, DP ;
MULLIN, JC ;
CANTILENA, LR .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1993, 269 (12) :1513-1518
[10]  
IKEYA Y, 1982, CHEM PHARM BULL, V30, P132